AIML and BC Brain Wellness Program Launch Pilot to Explore the Heart–Brain Connection
AI/ML Innovations (OTCQB:AIMLF) has announced a strategic pilot project between its subsidiary Neural Cloud Solutions and the BC Brain Wellness Program (BCBWP). The collaboration will utilize Neural Cloud's MaxYield ECG technology to study the heart-brain connection in patients with neurological conditions.
The pilot represents the first deployment of MaxYield, an AI-driven ECG signal-enhancement engine, in a neurology-focused exercise program. The technology will analyze physiological data from individuals with conditions like Parkinson's disease, stroke, and multiple sclerosis during supervised exercise settings to understand how cardiac responses may correlate with neurological status and outcomes.
This initiative aims to verify the algorithm's performance in real-world settings and establish groundwork for future research collaborations, focusing on condition-specific cardiac responses and potential HR/HRV biomarkers.
AI/ML Innovations (OTCQB:AIMLF) ha annunciato un progetto pilota strategico tra la sua controllata Neural Cloud Solutions e il BC Brain Wellness Program (BCBWP). La collaborazione sfrutterà la tecnologia MaxYield ECG di Neural Cloud per studiare la connessione cuore-mente in pazienti con condizioni neurologiche.
Il pilota rappresenta la prima applicazione di MaxYield, un motore di potenziamento dei segnali ECG guidato dall'IA, in un programma di esercizio focalizzato sulla neurologia. La tecnologia analizzerà dati fisiologici di individui con condizioni come malattia di Parkinson, ictus e sclerosi multipla durante sessioni di esercizio supervisionato per comprendere come le risposte cardiache possano correlarsi allo stato neurologico e agli esiti.
Questa iniziativa mira a verificare la performance dell'algoritmo in contesti reali e a gettare le basi per future collaborazioni di ricerca, concentrandosi su risposte cardiache specifiche per condizione e su potenziali biomarcatori HR/HRV.
AI/ML Innovations (OTCQB:AIMLF) ha anunciado un proyecto piloto estratégico entre su filial Neural Cloud Solutions y el BC Brain Wellness Program (BCBWP). La colaboración utilizará la tecnología MaxYield ECG de Neural Cloud para estudiar la conexión corazón-cerebro en pacientes con afecciones neurológicas.
El piloto representa la primera implementación de MaxYield, un motor de mejora de señales ECG impulsado por IA, en un programa de ejercicios centrado en la neurología. La tecnología analizará datos fisiológicos de personas con condiciones como enfermedad de Parkinson, ictus y esclerosis múltiple durante entornos de ejercicio supervisado para entender cómo las respuestas cardíacas pueden correlacionarse con el estado neurológico y los resultados.
Esta iniciativa tiene como objetivo verificar el rendimiento del algoritmo en entornos reales y sentar las bases para futuras colaboraciones de investigación, enfocándose en respuestas cardíacas específicas por condición y posibles biomarcadores HR/HRV.
AI/ML Innovations (OTCQB:AIMLF)는 자회사 Neural Cloud Solutions와 BC Brain Wellness Program(BCBWP) 간의 전략적 파일럿 프로젝트를 발표했습니다. 협업은 Neural Cloud의 MaxYield ECG 기술을 활용하여 신경학적 질환이 있는 환자의 심장-뇌 연결고리를 연구합니다.
이 파일럿은 신경학 분야의 운동 프로그램에서 최초로 AI 기반 ECG 신호 향상 엔진인 MaxYield를 배치하는 것을 의미합니다. 이 기술은 파킨슨병, 뇌졸중, 다발성 경화증 등과 같은 질환을 가진 개인의 생리 데이터를 감독하에 수집하여 심장 반응이 신경학적 상태와 결과와 어떤 상관관계가 있는지 이해합니다.
이 이니셔티브의 목표는 실제 환경에서 알고리즘의 성능을 확인하고 앞으로의 연구 협력을 위한 토대를 마련하는 것으로, 질환별 심장 반응과 잠재적 HR/HRV 바이오마커에 초점을 맞춥니다.
AI/ML Innovations (OTCQB:AIMLF) a annoncé un projet pilote stratégique entre sa filiale Neural Cloud Solutions et le BC Brain Wellness Program (BCBWP). La collaboration utilisera la technologie MaxYield ECG de Neural Cloud pour étudier la connexion cœur-cerveau chez les patients atteints de troubles neurologiques.
Le pilote représente la première déploiement de MaxYield, un moteur d’amélioration des signaux ECG piloté par l’IA, dans un programme d’exercice axé sur la neurologie. La technologie analysantera les données physiologiques des personnes souffrant de Parkinson, d’accident vasculaire cérébral et de sclérose en plaques pendant des séances d’exercice supervisées afin de comprendre comment les réponses cardiaques peuvent être corrélées à l’état neurologique et aux résultats.
Cette initiative vise à vérifier les performances de l’algorithme en conditions réelles et à poser les bases de futures collaborations de recherche, en se concentrant sur les réponses cardiaques spécifiques à chaque maladie et sur d’éventuels biomarqueurs HR/HRV.
AI/ML Innovations (OTCQB:AIMLF) hat ein strategisches Pilotprojekt zwischen der Tochtergesellschaft Neural Cloud Solutions und dem BC Brain Wellness Program (BCBWP) angekündigt. Die Zusammenarbeit wird die MaxYield ECG-Technologie von Neural Cloud nutzen, um die Herz-Gehirn-Verbindung bei Patienten mit neurologischen Erkrankungen zu untersuchen.
Der Pilot stellt die erste Bereitstellung von MaxYield, einer KI-gesteuerten Engine zur Verbesserung von ECG-Signalen, in einem auf Neurologie fokussierten Übungsprogramm dar. Die Technologie wird physiologische Daten von Personen mit Erkrankungen wie Parkinson, Schlaganfall und Multipler Sklerose während beaufsichtigter Übungssitzungen analysieren, um zu verstehen, wie Herzreaktionen mit dem neurologischen Zustand und den Ergebnissen korrelieren könnten.
Diese Initiative zielt darauf ab, die Leistung des Algorithmus in realen Umgebungen zu überprüfen und die Grundlage für zukünftige Forschungskooperationen zu schaffen, mit Fokus auf krankheitsspezifische Herzreaktionen und potenzielle HR/HRV-Biomarker.
AI/ML Innovations (OTCQB:AIMLF) أعلنت عن مشروع تجريبي استراتيجي بين شركتها الفرعية Neural Cloud Solutions وبرنامج BC Brain Wellness (BCBWP). ستستخدم التعاون تكنولوجيا MaxYield ECG من Neural Cloud لدراسة ارتباط القلب بالدماغ لدى المرضى المصابين بحالات عصبية.
يمثل هذا التجريبي أول تطبيق لـ MaxYield، محرك تعزيز إشارات ECG القائم على الذكاء الاصطناعي، في برنامج تمارين يركّز على علم الأعصاب. ستقوم التكنولوجيا بتحليل البيانات الفسيولوجية من أشخاص يعانون من أمراض مثل مرض باركنسون، السكتة الدماغية والتصلب المتعدد أثناء بيئات تمرين تحت إشراف لفهم كيف يمكن أن تت correlate استجابات القلب بالحالة العصبية والنتائج.
تهدف هذه المبادرة إلى التحقق من أداء الخوارزمية في بيئات العالم الحقيقي وتأسيس الأساس للتعاونات البحثية المستقبلية، مع التركيز على الاستجابات القلبية الخاصة بكل حالة والاحتمالات لمؤشرات HR/HRV.
AI/ML Innovations (OTCQB:AIMLF) 宣布其子公司 Neural Cloud Solutions 与 BC Brain Wellness Program (BCBWP) 之间的战略试点项目。该合作将利用 Neural Cloud 的 MaxYield ECG 技术 来研究患有神经疾病的患者的心脑连接。
该试点是 MaxYield 的首次部署，一种由 AI 驱动的心电信号增强引擎，应用于以神经科为焦点的运动计划中。该技术将 在监督的运动环境中分析患有帕金森病、脑卒中和多发性硬化等疾病的个体的生理数据，以了解心脏反应与神经状态和结果之间的相关性。
这一举措旨在在真实世界环境中验证算法的表现，并为未来的研究合作奠定基础，重点关注按病种划分的心脏反应和潜在的 HR/HRV 生物标志物。
- First real-world application of MaxYield ECG technology in neurology
- Strategic expansion of technology beyond cardiology into neurology and wellness research
- Partnership with established medical program (BC Brain Wellness Program)
- Potential to develop new biomarkers and insights for neurological conditions
- Early-stage pilot with no guaranteed outcomes
- No immediate revenue generation mentioned
- Technology still in verification phase
Leveraging MaxYield™ ECG to capture real-world exercise data in people living with neurological conditions
Generating actionable insights into how cardiac responses may correlate with brain health and outcomes
TORONTO, ON / ACCESS Newswire / September 30, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leader in AI-powered signal interpretation, is pleased to announce a pilot project between its wholly owned subsidiary, Neural Cloud Solutions Inc. ("Neural Cloud"), and the BC Brain Wellness Program ("BCBWP"), a lifestyle-based intervention program with a comprehensive and integrated approach to brain wellness for people living with Parkinson's Disease, Multiple Sclerosis, strokes, and other chronic brain conditions. The program also supports care partners, and healthy agers as an upstream proactive approach to improving health and quality of life. The program empowers individuals to take preventative action themselves by offering ongoing, proactive lifestyle-based interventions such as exercise, nutrition, mind-body and arts-based interventions that can have a significant impact on quality of life, condition management, and prevention.
The pilot will focus on applying Neural Cloud's MaxYield ECG technology in a supervised exercise setting to evaluate its feasibility and practical utility in capturing and analyzing physiological data from individuals with neurological conditions.
This initiative represents the first deployment of MaxYield, Neural Cloud's AI-driven ECG signal-enhancement engine, within a neurology-focused exercise program. By denoising and structuring ECG data, MaxYield enables reliable labeling and analysis that can uncover patterns of heart activity and variability (HR/HRV) across participants with conditions such as Parkinson's disease, stroke, and multiple sclerosis. The data will help evaluate whether exercise produces measurable cardiac responses that may correlate with neurological status and outcomes.
Dr. Silke Cresswell, Co-Founder of the BC Brain Wellness Program, commented: "Our program is dedicated to exploring how exercise and lifestyle interventions can improve quality of life and outcomes for people living with neurological disorders. The nervous system and the heart constantly interact with each other which is particularly important during exercise. Partnering with AIML allows us to investigate the cardiac signals to better understand this bidirectional relationship and the benefits of exercise for both heart and brain."
"We are excited to explore how our platform can contribute to the growing understanding of the heart-brain connection," said Esmat Naikyar, President of Neural Cloud Solutions Inc. and Chief Product Officer at AIML. "This pilot is an important step in verifying how our algorithms perform in real-world, exercise-based settings and how they may add value to future clinical research."
Paul Duffy, Executive Chairman and CEO of AIML, added: "This collaboration underscores our strategy to expand MaxYield™ beyond cardiology into adjacent domains such as neurology and wellness research. By working with the BC Brain Wellness Program, we are demonstrating how AI can bridge disciplines and generate new insights that improve care."
The project will serve as a product verification phase, laying the groundwork for future research collaborations. As wearable ECG data is collected, the pilot will examine condition-specific cardiac responses, potential HR/HRV biomarkers, and how exercise influences neurocardiac dynamics.
With this initiative, AIML and BCBWP are helping to turn the long-acknowledged but poorly understood heart-brain connection into structured, measurable, and actionable insights.
About the BC Brain Wellness Program
Established in 2019 by UBC faculty Dr. Silke Appel-Cresswell and Dr. Jack Taunton, the BC Brain Wellness Program (BCBWP, www.bcbrainwellness.ca) at the Djavad Mowafaghian Centre for Brain Health empowers people living with chronic brain conditions and their care partners to play a proactive role in their wellbeing while addressing important gaps in the health care system and contributing to the education of the next generation of health care professionals. The evidence-based, highly interdisciplinary program integrates research, education, and program delivery of lifestyle interventions, featuring exercise, diet, mind-body, arts-based and social interventions. Lifelong exercise and healthy nutrition are some of the most potent tools to improve health outcomes across different organ systems and to tackle the epidemic of chronic, non-communicable diseases. BCBWP research projects comprehensively interrogate different organ systems to optimize prevention and interventions for chronic brain conditions. BCBWP programming extends care beyond the traditional, sporadic and reactive care model by providing preventive and sustained support for individuals living with brain conditions, their care partners and healthy agers. In an era of increasing social isolation and loneliness with associated poor health outcomes, ongoing group classes foster community while also providing a cost-effective approach. The BCBWP offers both in-person and virtual classes which improves access to frequently underserved rural and remote areas. The program contributes to the education and training of future healthcare professionals, equipping them to better support the increasing number of individuals affected by brain conditions and advancing workforce preparedness.
For more information about AIML:
For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.
Contact:
Blake Fallis
(778) 405-0882
info@aiml.health
About AIML Innovations Inc.
AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Its proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable insights-supporting earlier diagnosis, personalized treatment, and more effective care.
AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).
On behalf of the Board of Directors:
Paul Duffy, Executive Chairman & CEO
Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation and future research applications of MaxYield™. Such statements are subject to numerous uncertainties, and actual results may differ materially. Readers should not place undue reliance on forward-looking statements.
SOURCE: AI/ML Innovations, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the purpose of AIMLF's partnership with BC Brain Wellness Program?
How will AIMLF's MaxYield technology be used in neurological research?
What conditions will be studied in AIMLF's pilot program?
What are the potential benefits of AIMLF's MaxYield technology in neurology?
When will AIMLF's neurological pilot program begin?
